What is Caris Life Sciences? Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine ...

Review quarterly and annual revenue, net income, and cash flow for Caris Life Sciences Inc (CAI:XNAS) stock through the last fiscal year.

Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy ...

Caris Life Sciences spikes by over 30% in IPO debut, embraces AI as future of oncology In an interview, the company’s president said cancer doctors need not be afraid of machine learning.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its ...

Caris Life Sciences is undergoing an aggressive expansion phase, combining advances in artificial intelligence with deep molecular insights to drive the evolution of personalized medicine.

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the range it first proposed last week, in the vicinity of $400 million.

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO ...

When is Caris Life Sciences’s IPO? Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20.